Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Deciding which card is better, cash back or rewards, requires consideration of your spending habits. Make the right choice for your finances.
26,157 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Nvidia’s new AI architectures debuted at GTC 2026, signaling a longer-term AI infrastructure push. Here’s what that m...
A zero-premium Part D plan can still trigger the IRMAA surcharge, adding as much as $91 a month for certain retirees....
Public interest in Matthew Perry's passing sparked conversations beyond celebrity trivia. This article dives into rev...
As Medicare Part B costs climb in 2026, delaying enrollment can trigger lifelong penalties. Experts warn retirees to ...
Many investors wonder if a single crypto move can change everything. This guide breaks down XRP's potential, the risk...
Anthropic is reshaping the AI landscape. This article explains why the company could become a major force in software...
A CEO’s drastic HR purge and a high-profile EEOC lawsuit against The New York Times collide at a moment of market vol...
A high-profile insider move hits Impinj as a director sells 33,000 impinj shares. Learn what this signals, how to ana...
A wave of AI demand and energy-cost pressures are reviving interest in crypto operators who pivot to AI compute. The ...
A new software-first speed boost from DeepSeek challenges Nvidia's layered hardware strategy. This deep dive explains...
Anterix stock surged 140% as a major investor disclosed a multi-million dollar buy. This article breaks down the driv...